Home/Filings/4/0001628280-25-001204
4//SEC Filing

Wise John Drayton 4

Accession 0001628280-25-001204

CIK 0001104506other

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 6:45 PM ET

Size

17.8 KB

Accession

0001628280-25-001204

Insider Transaction Report

Form 4
Period: 2025-01-07
Wise John Drayton
Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2025-01-08+31,93031,930 total
    Exercise: $65.72Exp: 2035-01-08Common Stock (31,930 underlying)
  • Sale

    Common Stock

    2025-01-07$65.98/sh10,000$659,800122,492 total
  • Sale

    Common Stock

    2025-01-10$65.40/sh287$18,770125,562 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-01-0710,0000 total
    Exercise: $16.07Exp: 2025-01-08Common Stock (10,000 underlying)
  • Sale

    Common Stock

    2025-01-07$65.87/sh2,908$191,550119,584 total
  • Sale

    Common Stock

    2025-01-08$66.21/sh392$25,954119,192 total
  • Award

    Common Stock

    2025-01-08+6,657125,849 total
  • Exercise/Conversion

    Common Stock

    2025-01-07$16.07/sh+10,000$160,700132,492 total
Footnotes (8)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  • [F2]Includes 835 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
  • [F3]Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.
  • [F4]This is the weighted average sales price representing 2,908 shares sold at prices ranging from $65.84 to $65.93 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F5]Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
  • [F6]Each RSU was granted on January 8, 2025 for no consideration.
  • [F7]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
  • [F8]These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Issuer

INSMED Inc

CIK 0001104506

Entity typeother

Related Parties

1
  • filerCIK 0001930805

Filing Metadata

Form type
4
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 6:45 PM ET
Size
17.8 KB